Omni

From Tobacco Products

Jump to: navigation, search

Date: 20011201
Markets: Nationwide roll out

Contents

Manufacturer

Vector Tobacco, Ltd.
Vector Group Ltd.

Description

Cigarette containing reduced carcinogen tobacco and a carbon filter. Available in full-flavor, lights, ultra lights. Menthol version planned.

Claims

Reduced Carcinogens. Premium Taste Tobacco is processed by a new method, including a palladium treatment. The first premium cigarette created to significantly reduce carcinogenic PAHs, nitrosamines, and catechols, which are the major causes of lung cancer.

Product Design Features

  • Conventional style cigarette containing tobacco treated with palladium,which acts as a catalyst for the removal of carcinogens
  • Claims to significantly reduce PAHs, nitrosamines, catechols


Images

Media

Publications

Industry Documents

Links

Market Testing

  • No known market testing

Advertising and Selling Messages

  • Newspaper and magazine ads claimed that Omni was “created to

significantly reduce carcinogenic PAHs, nitrosamines, and catechols,which are major causes of lung cancer in smokers”

  • A Vector Tobacco website claimed Omni produced a 53% reduction

in exposure to NNK (a potent lung carcinogen) and a 15% to 20% reduction in pyrene (a marker for PAH exposure), as measured by machine-derived yields

  • Slogan: “Reduced Carcinogens. Premium Taste.”

Packaging

  • Red, gold, or silver soft pack featuring Omni brand with large, distinctive “O”
  • Available in regular, lights, and ultralights, in both king and 100 varieties
  • Omni Free, a cigarette designed to have no nicotine, was later rebranded as Quest (See pages 27-28)[1]

Use and the Consumer

  • Available from 2001 to 2006 throughout the US in select stores

Smoke Emissions and Human Use

  • FTC (standard) method, according to Vector: CO: no significant

reduction; NNK: -53%; pyrene: -20%

  • FTC (standard) method, according to outside researchers, showed

smaller effects: CO: no significant reduction; NNK: -21%; pyrene: -5%; formaldehyde +68%; nitric oxide +168%

  • Massachusetts: not yet conducted or not available
  • Health Canada: significant increases in formaldehyde (26%) and nitric oxide (150%)
  • Topography: Smokers who switched to Omni: smoked less intensively; had lower total cotinine levels than with their regular cigarettes;increased CO; had an apparent slight decrease of carcinogen,but not significantly; reduced total NNAL levels (not 1-HOPlevels) statistically significantly
  • Human exposure: not yet conducted or not available

Toxicity Analyses

  • Ames method in vitro: not yet conducted or not available
  • In vivo MSP: not yet conducted or not available
  • Animal exposure: not yet conducted or not available

Legal Compliance

  • Surgeon General warnings
  • No sales to minors
  • Subject to State and Federal cigarette taxes

Community Response

  • Petition submitted to the FDA in 2001 urging jurisdiction over

Omni; specifically, that Omni should be regulated as a “drug” due to Omni’s claims of “reduced carcinogens”

Patents

Early related Palladium treatment - 1968 - Liggett and Meyers

Notes

Personal tools